Cabaletta Bio prices $100M public offering of common stock and warrants to fund rese-cel development

Cabaletta Bio, Inc.

Offering includes 39.2M shares and 50M warrants at combined price of $2.00 per unit; net proceeds ~$94M.
Also offers 10.8M pre-funded warrants at $1.99999 per unit for certain investors.
Underwriters have 30-day option to purchase up to an additional 15M shares and/or warrants.
Proceeds to fund expanded clinical development of rese-cel, including potential registrational studies, and manufacturing readiness.
Cash runway expected into second half of 2026 based on current operating plan.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.